published: 01 Nov 2011
last updated: 14 Nov 2011
General Information
Contact person submitting the report
9. Organizations/stakeholders who were consulted or participated in the preparation of this report
10. Time period covered by this report
Party to the Cartagena Protocol on Biosafety
12. Is your country a Party to the Cartagena Protocol on Biosafety (CPB)?
13. If you answered No to question 12, is there any national process in place towards becoming a Party?
14. Here you may provide further details
Article 2 – General provisions
15. Has your country introduced the necessary legal, administrative and other measures for the implementation of the Protocol?
16. Which specific instruments are in place for the implementation of your national biosafety framework?
One or more national biosafety laws
One or more national biosafety regulations
Other laws, regulations or guidelines that indirectly apply to biosafety
17. Has your country established a mechanism for the budgetary allocations of funds for the operation of its national biosafety framework?
18. Does your country have permanent staff to administer functions directly related to the national biosafety framework?
19. If you answered Yes to question 18, how many permanent staff members are in place whose functions are directly related to the national biosafety framework?
20. Has your country’s biosafety framework / laws / regulations / guidelines been submitted to the Biosafety Clearing-House (BCH)?
21. Here you may provide further details on the implementation of Article 2 in your country:
Article 5 – Pharmaceuticals
22. Does your country regulate the transboundary movement, handling and use of living modified organisms (LMOs) which are pharmaceuticals?
23. If you answered Yes to question 22, has this information been submitted to the BCH?
24. Here you may provide further details on the implementation of Article 5 in your country:
Article 6 – Transit and Contained use
25. Does your country regulate the transit of LMOs?
26. Does your country regulate the contained use of LMOs?
27. If you answered Yes to questions 25 or 26, has this information been submitted to the BCH?
28. Here you may provide further details on the implementation of Article 6 in your country:
Articles 7 to 10 – Advance Informed Agreement (AIA) and intentional introduction of LMOs into the environment
29. Has your country adopted law(s) / regulations / administrative measures for the operation of the AIA procedure of the Protocol?
30. Has your country adopted a domestic regulatory framework consistent with the Protocol regarding the transboundary movement of LMOs for intentional introduction into the environment?
31. Has your country established a mechanism for taking decisions regarding first intentional transboundary movements of LMOs for intentional introduction into the environment?
32. If you answered Yes to question 31, does the mechanism also apply to cases of intentional introduction of LMOs into the environment that were not subject to transboundary movement?
33. Has your country established a mechanism for monitoring potential effects of LMOs that are released into the environment?
34. Does your country have the capacity to detect and identify LMOs?
35. Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure?
36. Has your country established legal requirements for the accuracy of information contained in the notification?
37. Has your country ever received an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
38. Has your country ever taken a decision on an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
39. If you answered Yes to question 38, how many LMOs has your country approved to date for import for intentional introduction into the environment?
40. If you answered Yes to question 38, how many LMOs, not imported, has your country approved to date for intentional introduction into the environment?
41. In the current reporting period, how many applications/notifications has your country received regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
42. In the current reporting period, how many decisions has your country taken regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
43. With reference to the decisions taken on intentional transboundary movements of LMOs for intentional introduction into the environment, has your country received a notification from the Party(ies) of export or from the exporter(s) prior to the transboundary movement?
44. Did the notifications contain complete information (at a minimum the information specified in Annex I of the Cartagena Protocol on Biosafety)?
45. Has your country acknowledged receipt of the notifications to the notifier within ninety days of receipt?
46. Has your country informed the notifier(s) and the BCH of its decision(s)?
47. Has your country informed the notifier(s) and the BCH of its decision(s) in due time (within 270 days or the period specified in your communication to the notifier)?
48. What percentage of your country’s decisions fall into the following categories?
49. In cases where your country approved an import with conditions or prohibited an import, did it provide reasons on which its decisions were based to the notifier and the BCH?
50. Here you may provide further details on the implementation of Articles 7-10 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs for intentional introduction to the environment:
Article 11 – Procedure for living modified organisms intended for direct use as food or feed, or for processing (LMOs-FFP)
51. Has your country adopted specific law(s) or regulation(s) for decision-making regarding domestic use, including placing on the market, of LMOs-FFP?
52. Has your country established legal requirements for the accuracy of information to be provided by the applicant?
53. Has your country established a mechanism to ensure that decisions regarding LMOs-FFP that may be subject to transboundary movement will be communicated to the Parties through the BCH?
54. Has your country established a mechanism for taking decisions on the import of LMOs-FFP?
55. Has your country declared through the BCH that in the absence of a regulatory framework its decisions prior to the first import of an LMO-FFP will be taken according to Article 11.6 of the Cartagena Protocol on Biosafety?
56. Has your country indicated its needs for financial and technical assistance and capacity building in respect of LMOs-FFP?
57. Has your country ever taken a decision on LMOs-FFP (either on import or domestic use)?
58. How many LMOs-FFP has your country approved to date?
59. In the current reporting period, how many decisions has your country taken regarding the import of LMOs-FFP?
60. In the current reporting period, how many decisions has your country taken regarding domestic use, including placing on the market, of LMOs-FFP?
61. Has your country informed the Parties through the BCH of its decision(s) regarding import, of LMOs-FFP?
62. Has your country informed the Parties through the BCH of its decision(s) regarding domestic use, including placing on the market, of LMOs-FFP within 15 days?
63. Here you may provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs-FFP:
Article 12 – Review of decision
64. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs?
65. Has your country ever received a request for a review of a decision?
66. Has your country ever reviewed / changed a decision regarding an intentional transboundary movement of LMOs?
67. In the current reporting period, how many decisions were reviewed and/or changed regarding an intentional transboundary movement of an LMO?
68. Has your country informed the notifier and the BCH of the review and/or changes in the decision?
69. Has your country informed the notifier and the BCH of the review and changes in the decision within thirty days?
70. Has your country provided reasons to the notifier and the BCH for the review and/or changes in the decision?
71. Here you may provide further details on the implementation of Article 12 in your country:
Article 13 – Simplified procedure
72. Has your country established a system for the application of the simplified procedure regarding an intentional transboundary movement of LMOs?
73. Has your country ever applied the simplified procedure?
74. If you answered Yes to question 73, has your country informed the Parties through the BCH of the cases where the simplified procedure applies?
75. In the current reporting period, how many LMOs has your country applied the simplified procedure to?
76. Here you may provide further details on the implementation of Article 13 in your country:
Article 14 – Bilateral, regional and multilateral agreements and arrangements
77. Has your country entered into any bilateral, regional or multilateral agreements or arrangements?
78. If you answered Yes to question 77, has your country informed the Parties through the BCH of the agreements or arrangements?
79. If you answered Yes to question 77, please provide a brief description of the scope and objective of the agreements or arrangements entered into:
80. Here you may provide further details on the implementation of Article 14 in your country:
Article 15 – Risk assessment
81. Has your country established a mechanism for conducting risk assessments prior to taking decisions regarding LMOs?
82. If you answered Yes to question 81, does this mechanism include procedures for identifying experts to conduct the risk assessments?
83. Has your country established guidelines for how to conduct risk assessments prior to taking decisions regarding LMOs?
84. Has your country acquired the necessary domestic capacity to conduct risk assessment?
85. Has your country established a mechanism for training national experts to conduct risk assessments?
86. Has your country ever conducted a risk assessment of an LMO for intentional introduction into the environment?
87. Has your country ever conducted a risk assessment of an LMO intended for direct use as food or feed, or for processing?
88. If your country has taken decision(s) on LMOs for intentional introduction into the environment or on domestic use of LMOs-FFP, were risk assessments conducted for all decisions taken?
89. Has your country submitted summary reports of the risk assessments to the BCH?
90. In the current reporting period, if your country has taken decisions regarding LMOs, how many risk assessments were conducted in the context of these decisions?
91. Has your country ever required the exporter to conduct the risk assessment(s)?
92. Has your country ever required the notifier to bear the cost of the risk assessment(s) of LMOs?
93. Here you may provide further details on the implementation of Article 15 in your country:
Article 16 – Risk management
94.1. LMOs for intentional introduction into the environment?
94.2. LMOs intended for direct use as food or feed, or for processing?
95. Has your country established and maintained appropriate measures to prevent unintentional transboundary movements of LMOs?
96. Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use?
97. Has your country cooperated with other Parties with a view to identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?
98. Has your country cooperated with other Parties with a view to taking measures regarding the treatment of LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?
99. Here you may provide further details on the implementation of Article 16 in your country, including any details regarding risk management strategies, also in case of lack of scientific certainty on potential adverse effects of LMOs:
Article 17 – Unintentional transboundary movements and emergency measures
100. Has your country made available to the BCH the relevant details setting out its point of contact for the purposes of receiving notifications under Article 17?
101. Has your country established a mechanism for addressing emergency measures in case of unintentional transboundary movements of LMOs that are likely to have significant adverse effect on biological diversity?
102. Has your country implemented emergency measures in response to information about releases that led, or may have led, to unintentional transboundary movements of LMOs?
103. In the current reporting period, how many times has your country received information concerning occurrences that led, or may have led, to unintentional transboundary movement(s) of one or more LMOs to or from territories under its jurisdiction?
104. Has your country notified affected or potentially affected States, the BCH and, where appropriate, relevant international organizations, of the above release?
105. If you answered Yes to question 104, who did your country notify?
106. Has your country immediately consulted the affected or potentially affected States to enable them to determine appropriate responses and initiate necessary action, including emergency measures?
107. Here you may provide further details on the implementation of Article 17 in your country:
Article 18 – Handling, transport, packaging and identification
108. Has your country taken measures to require that LMOs that are subject to transboundary movement are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards?
109. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is not known through means such as identity preservation systems, they may contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
110. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is known through means such as identity preservation systems, they contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
111. Has your country taken measures to require that documentation accompanying LMOs that are destined for contained use clearly identifies them as living modified organisms and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned?
112. Has your country taken measures to require that documentation accompanying LMOs that are intended for intentional introduction into the environment of the Party of import, clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter?
113. Does your country have the capacity to enforce the requirements of identification and documentation of LMOs?
114. Has your country established procedures for the sampling and detection of LMOs?
115. Here you may provide further details on the implementation of Article 18 in your country:
Article 19 – Competent National Authorities and National Focal Points
116. Has your country designated one national focal point for the Cartagena Protocol to be responsible for liaison with the Secretariat?
117. Has your country designated one national focal point for the Biosafety Clearing-House to liaise with the Secretariat regarding issues of relevance to the development and implementation of the BCH?
118. Has your country designated one or more competent national authorities, which are responsible for performing the administrative functions required by the Cartagena Protocol on Biosafety and are authorized to act on your country’s behalf with respect to those functions?
119. In case your country designated more than one competent national authority, has your country conveyed to the Secretariat the respective responsibilities of those authorities?
120. Has your country made available the required information referred in questions 116-119 to the BCH?
121. In case your country has designated more than one competent national authority, has your country established a mechanism for the coordination of their actions prior to taking decisions regarding LMOs?
122. Has your country established adequate institutional capacity to enable the competent national authority(ies) to perform the administrative functions required by the Cartagena Protocol on Biosafety?
123. Here you may provide further details on the implementation of Article 19 in your country:
Article 20 – Information Sharing and the Biosafety Clearing-House (BCH)
124.a. Existing national legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3 (a))
124.b. National laws, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5)
124.c. Bilateral, multilateral and regional agreements and arrangements (Articles 14, paragraph 2 and 20, paragraph 3 (b))
124.d. Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3 (e))
124.e. Reports submitted by the Parties on the operation of the Protocol (Article 20, paragraph 3 (e))
124.f. Decisions by a Party on regulating the transit of specific living modified organisms (LMOs) (Article 6, paragraph 1)
124.g. Occurrence of unintentional transboundary movements that are likely to have significant adverse effects on biological diversity (Article 17, paragraph 1)
124.h. Illegal transboundary movements of LMOs (Article 25, paragraph 3)
124.i. Final decisions regarding the importation or release of LMOs (i.e. approval or prohibition, any conditions, requests for further information, extensions granted, reasons for decision) (Articles 10, paragraph 3 and 20, paragraph 3(d))
124.j. Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4)
124.k. Final decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1)
124.l. Final decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with annex III (Article 11, paragraph 6) (requirement of Article 20, paragraph 3(d))
124.m. Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6)
124.n. Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1)
124.o. LMOs granted exemption status by each Party (Article 13, paragraph 1)
124.p. Cases where intentional transboundary movement may take place at the same time as the movement is notified to the Party of import (Article 13, paragraph 1)
124.q. Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3 (c))
125. Has your country established a mechanism for strengthening the capacity of the BCH National Focal Point to perform its administrative functions?
126. Has your country established a mechanism for the coordination among the BCH National Focal Point, the Cartagena Protocol focal point, and the competent national authority(ies) for making information available to the BCH?
127. Does your country use the information available in the BCH in its decision making processes on LMOs?
128. Has your country experienced difficulties accessing or using the BCH?
129. If you answered Yes to question 128, has your country reported these problems to the BCH or the Secretariat?
130. Is the information submitted by your country to the BCH complete and up-to date?
131. Here you may provide further details on the implementation of Article 20 in your country:
Article 21 – Confidential information
132. Has your country established procedures to protect confidential information received under the Protocol?
133. Does your country allow the notifier to identify information that is to be treated as confidential?
134. Here you may provide further details on the implementation of Article 21 in your country:
Article 22 – Capacity-building
135. Has your country received external support or benefited from collaborative activities with other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
136. If you answered Yes to question 135, how were these resources made available?
137. Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
138. If you answered Yes to question 137, how were these resources made available?
139. Is your country eligible to receive funding from the Global Environment Facility (GEF)?
140. Has your country ever initiated a process to access GEF funds for building capacity in biosafety?
141. If you answered Yes to question 140, how would you characterize the process?
142. Has your country ever received funding from the GEF for building capacity in biosafety?
143. During the current reporting period, has your country undertaken activities for the development and/or strengthening of human resources and institutional capacities in biosafety?
144. If you answered Yes to question 143, in which of the following areas were these activities undertaken?
Human resources capacity development and training
Risk assessment and other scientific and technical expertise
Information exchange and data management including participation in the Biosafety Clearing-House
Scientific, technical and institutional collaboration at subregional, regional and international levels
145. During the current reporting period, has your country carried out a capacity-building needs assessment?
146. Does your country still have capacity-building needs?
147. If you answered Yes to question 146, indicate which of the following areas still need capacity-building.
Institutional capacity
Human resources capacity development and training
Risk assessment and other scientific and technical expertise
Risk management
Public awareness, participation and education in biosafety
Identification of LMOs, including their detection
148. Has your country developed a capacity-building strategy or action plan?
149. Has your country submitted the details of national biosafety experts to the Roster of Experts in the BCH?
150. Here you may provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds:
Article 23 – Public awareness and participation
151. Has your country established a strategy or put in place legislation for promoting and facilitating public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
152. Has your country established a biosafety website?
153. Has your country established a mechanism to ensure public access to information on living modified organisms that may be imported?
154. Has your country established a mechanism to consult the public in the decision-making process regarding LMOs?
155. Has your country established a mechanism to make available to the public the results of decisions taken on LMOs?
156. Has your country taken any initiative to inform its public about the means of public access to the Biosafety Clearing-House?
157. In the current reporting period, has your country promoted and facilitated public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
158. If you answered Yes to question 157, has your country cooperated with other States and international bodies?
159. In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs and made the results of such decisions available to the public?
160. Here you may provide further details on the implementation of Article 23 in your country:
161. Has your country entered into any bilateral, regional, or multilateral agreement with non-Parties regarding transboundary movements of LMOs?
162. Has your country ever imported LMOs from a non-Party?
163. Has your country ever exported LMOs to a non-Party?
164. If you answered Yes to questions 162 or 163, were the transboundary movements of LMOs consistent with the objective of the Cartagena Protocol on Biosafety?
165. If you answered Yes to questions 162 or 163, was information about these transboundary movements submitted to the BCH?
166. If your country is not a Party to the Cartagena Protocol, has it contributed information to the BCH on LMOs released in, or moved into, or out of, areas within its national jurisdiction?
167. Here you may provide further details on the implementation of Article 24 in your country:
Article 25 – Illegal transboundary movements
168. Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement this Protocol?
169. Has your country established a strategy for detecting illegal transboundary movements of LMOs?
170. In the current reporting period, how many times has your country received information concerning cases of illegal transboundary movements of an LMO to or from territories under its jurisdiction?
171. Has your country informed the BCH and the other Party(ies) involved?
172. Has your country established the origin of the LMO(s)?
173. Has your country established the nature of the LMO(s)?
174. Has your country established the circumstances of the illegal transboundary movement(s)?
175. Here you may provide further details on the implementation of Article 25 in your country:
Article 26 – Socio-economic considerations
176. If your country has taken a decision on import, has it ever taken into account socio-economic considerations arising from the impact of the LMO on the conservation and sustainable use of biological diversity?
177. Has your country cooperated with other Parties on research and information exchange on any socio-economic impacts of LMOs?
178. Here you may provide further details on the implementation of Article 26 in your country:
Article 27 – Liability and Redress
179. Has your country signed the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress?
180. Has your country initiated steps towards ratification, acceptance or approval of the Nagoya-Kuala Lumpur Supplementary Protocol?
181. Here you may provide further details on any activities undertaken in your country towards the implementation of the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress:
Article 33 – Monitoring and reporting
182. Has your country submitted the previous national reports (Interim and First National Reports)?
183. If your country did not submit previous reports, indicate the main challenges that hindered the submission
No obligation to submit (e.g. country was not a Party at the time)
184. Please use this field to provide any other information on issues related to national implementation of the Protocol, including any obstacles or impediments encountered.
Comments on reporting format
185. Please use this field to provide any other information on difficulties that you have encountered in filling in this report.
Survey on indicators of the Strategic Plan (2014)
3. When did your national biosafety framework become operational?
4. How many biosafety short-term training programmes and/or academic courses are offered annually in your country?
5. Does your country have in place a functional national mechanism for coordinating biosafety capacity-building initiatives?
6. How much additional funding (in the equivalent of US dollars) has your country mobilized in the last four years to support implementation of the Biosafety Protocol, beyond the regular national budgetary allocation?
7. Does your country have predictable and reliable funding for building capacity for the effective implementation of the Protocol?
8. How many LMO-related collaborative bilateral/multilateral arrangements has your country established with other Parties/non-Parties?
9.a. Has your country adopted or used any guidance documents for the purpose of conducting risk assessment and/or risk management?
Risk assessment
9.b. Has your country adopted or used any guidance documents for the purpose of conducting risk assessment and/or risk management?
Risk management
10. Has your country adopted or used any guidance documents for the purpose of evaluating risk assessment reports submitted by notifiers?
11. Has your country adopted any common approaches to risk assessment with other countries?
12. Has your country ever conducted a risk assessment of an LMO?
13.a. Does your country have the capacity to identify, assess and/or monitor living modified organisms or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health?
Identify
13.b. Does your country have the capacity to identify, assess and/or monitor living modified organisms or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health?
Assess
13.c. Does your country have the capacity to identify, assess and/or monitor living modified organisms or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health?
Monitor
14. Does your country have available any guidance for the purpose of ensuring the safe handling, transport, and packaging of living modified organisms?
15. Does your country have any specific approaches or requirements that facilitate how socio-economic considerations should be taken into account in LMO decision making?
16. How many peer-reviewed published materials has your country used for the purpose of elaborating or determining national actions with regard to socio-economic considerations?
17. What is your country's experience, if any, in taking socio-economic considerations into account in LMO decision making?
18. Does your country have the capacity to take appropriate measures in the event that an LMO is unintentionally released?
19.a. How many people in your country have been trained in risk assessment, monitoring, management and control of LMOs?
Risk assessment
19.b. How many people in your country have been trained in risk assessment, monitoring, management and control of LMOs?
Monitoring
19.c. How many people in your country have been trained in risk assessment, monitoring, management and control of LMOs?
Management / Control
20. Does your country have the infrastructure (e.g. laboratory facilities) for monitoring or managing LMOs?
21. Is your country using training material and/or technical guidance for training in risk assessment and risk management of LMOs?
22.a. Are the available training materials and technical guidance on risk assessment and risk management of LMOs sufficient and effective?
Sufficient
22.b. Are the available training materials and technical guidance on risk assessment and risk management of LMOs sufficient and effective?
Effective
23. How many customs officers in your country have received training in the identification of LMOs?
24. How many laboratory personnel in your country have received training in detection of LMOs?
25. Does your country have reliable access to laboratory facilities for the detection of LMOs?
26. How many laboratories in your country are certified for LMO detection?
27. How many of the certified laboratories in the previous question are operational?
28. Has your country received any financial and/or technical assistance for capacity-building in the area of liability and redress relating to living modified organisms?
29. Does your country have administrative or legal instrument that provide for response measures for damage to biodiversity resulting from living modified organisms?
30. Has your country informed the public about existing modalities for public participation in the decision-making process regarding living modified organisms?
31. If you answered yes to the previous question, please indicate the modalities used to inform the public?
32. If you indicated multiple modalities for public participation in the question above, which one was most used?
33. How many academic institutions in your country are offering biosafety education and training courses and programmes?
34. How many biosafety training materials and/or online modules are available in your country?
35.a. Does your country have in place a monitoring and/or an enforcement system?
Monitoring system
35.b. Does your country have in place a monitoring and/or an enforcement system?
Enforcement system
36. Please indicate the number of regional, national and international events organized in relation to biosafety (e.g. seminars, workshops, press conferences, educational events, etc.,) in the last 2 years.
37. Please indicate the number of biosafety related publications that has been made available in your country in the last year.
38. If biosafety related publications were made available (see question above), please indicate which modalities were preferred.
39. How many collaborative initiatives (including joint activities) on the Cartagena Protocol and other Conventions and processes has your government established in the last 4 years?
40. Does your country have any awareness and outreach programmes on biosafety?
41. If you answered yes to the question above, please indicate what entity is responsible for carrying out the programmes and/or services and at which level the programmes take place.
42. Has your country designed and/or implemented an outreach/communication strategy on biosafety?
43. Please indicate the number of educational materials on biosafety that are available and accessible to the public.
